Drug Trial Radar · NCT02632708
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
153
Actual
Start
Dec 31, 2015
Primary completion
Dec 13, 2018
Study completion Jul 24, 2026
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Celgene Corporation
- First posted
- Dec 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy. The study plans to evaluate up to 2 dose levels of AG-120 in participants with an isocitrate dehydrogenase protein 1 (IDH1) mutation and up to 2 dose levels of AG-221 in participants with an isocitrate dehydrogenase protein 2 (IDH2) mutation. AG-120 or AG-221 will be administered with 2 types of AML induction therapies (cytarabine with either daunorubicin or idarubicin) and 2 types of AML consolidation therapies (mitoxantrone with etoposide \[ME\] or cytarabine). After consolidation therapy, participants may continue on to maintenance therapy and receive daily treatment with single-agent AG-120 or AG-221 until relapse, development of an unacceptable toxicity, or hematopoietic stem cell transplant (HSCT). The study will end when all participants have discontinued study treatment.
Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Untreated AML
- AML Arising From Myelodysplastic Syndrome (MDS)
- AML Arising From Antecedent Hematologic Disorder (AHD)
- AML Arising After Exposure to Genotoxic Injury
Interventions
AG-120Drug
AG-221Drug
cytarabineDrug
daunorubicinDrug
idarubicinDrug
mitoxantroneDrug
etoposideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse Events (AEs)Time frame: Up to 26 weeks
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
UCLA Medical Center
Los Angeles, California
University of Colorado
Aurora, Colorado
University of Chicago
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Ohio State University
Columbus, Ohio
Medical University of South Carolina - PPDS
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Universitatsklinikum Ulm
Ulm, Germany
VU Medisch Centrum
Amsterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.